The present invention, in some embodiments thereof, relates to a stopper driver for a drug delivery device and, more particularly, but not exclusively, to a telescoping stopper driver of a drug cartridge.
U.S. Pat. No. 6,800,071 discloses, “an improved pump, reservoir and reservoir piston for,” “controlled delivery of fluids. A motor is operably coupled to a drive member, such as a drive screw, which is adapted to advance a plunger slide in response to operation of the motor. The plunger slide is removably coupled to the piston. The piston comprises a first member and a second member. The first member has an external proximate side and an external distal side. The external proximate side is adapted to contact the fluid and is made of a material having a first stiffness. The second member has a first side and a second side and is at least partially disposed within the first member. The first side of the second member is adjacent to the external proximate side of the first member and is made of a material having a stiffness which is greater than the first stiffness.”
International Patent Application Publication No. WO/2011/090956 by the instant applicant (Cabiri) and/or U.S. Patent Application Publication No. 2009/0093792 to Gross.
Additional background art includes U.S. Patent Application Publication 20130304021, U.S. Patent Application Publication 20130296799, U.S. Patent Application Publication 20130245596, U.S. Pat. No. 8,465,455, International Patent Application Publication No. WO/2011/090956 and U.S. Patent Application Publication No. 2009/0093792.
According to an aspect of some embodiments of the invention, there is provided an assembly for driving a stopper in a drug reservoir of a drug delivery device comprising: a telescoping assembly that telescopes by relative rotation between at least a proximal shaft and a distal shaft oriented along and axis of the reservoir; the distal shaft configured to engage the stopper of the drug reservoir; an anti-rotational guide sized to move along the axis of the reservoir; the anti-rotational guide slidably and anti-rotationally coupled to a housing of the drug delivery device; a coupling slidably and anti-rotationally linking the anti-rotational guide to the distal shaft; the sliding and anti-rotation with respect to the axis of the reservoir such that rotating the proximal shaft with respect to the anti-rotational guide moves the distal shaft along the axis and moves the distal shaft with respect to the anti-rotational guide the anti-rotational guide also moving along the axis.
According to some embodiments of the invention, a maximum axial movement of the distal shaft with respect to the reservoir is greater than a maximum axial movement of the guide with respect to the reservoir.
According to some embodiments of the invention, the assembly further comprises: an intermediate shaft threadably engaged to the proximal shaft and to the distal shaft such that the telescoping assembly also telescopes by rotating the proximal shaft with respect to the intermediate shaft.
According to some embodiments of the invention, a maximum axial movement of the distal shaft with respect to the reservoir is greater than a maximum axial movement of the intermediate shaft with respect to the reservoir.
According to some embodiments of the invention, the assembly further comprises: a linear stabilizer coupled to the proximal shaft, inhibiting axial movement of the proximal shaft in a proximal direction with respect to the linear stabilizer, the linear stabilizer coupled to the reservoir inhibiting axial movement of the linear stabilizer in a proximal direction with respect to the reservoir, such that the rotation of the proximal shaft causes the distal shaft to advance distally inside of the drug reservoir.
According to some embodiments of the invention, the linear stabilizer includes a connector shaped to attach to a proximal portion of the reservoir.
According to some embodiments of the invention, the connector is shaped to attach to a flange of the reservoir.
According to some embodiments of the invention, the linear stabilizer includes an anti-rotational connector fitting to the housing for preventing rotation of the linear stabilizer with respect to the housing and wherein the anti-rotational guide slidably engages to the housing by means of the linear stabilizer.
According to some embodiments of the invention, the reservoir and the assembly form a cartridge and wherein the housing includes an opening fitting the cartridge and wherein the anti-rotational connector is shaped to connect to the housing to limit rotation of the anti-rotational connector with respect to the housing when the cartridge is inserted into the opening.
According to some embodiments of the invention, the assembly further comprises: a bearing preventing proximal movement of the proximal shaft with respect to the housing and allowing rotation of the proximal shaft with respect to the housing.
According to some embodiments of the invention, the assembly further comprises a stopper interface for driving the stopper; the interface is optionally connected to the distal shaft.
According to some embodiments of the invention, the coupling includes a protrusion slidably inserted into a track.
According to an aspect of some embodiments of the invention, there is provided a method of supplying a drug to a delivery device comprising: providing a reservoir containing a drug and sealed with a stopper and a telescoping assembly that telescopes by rotating a proximal shaft with respect to a distal shaft; the distal shaft configured to engage the stopper; slidably and anti-rotationally engaging an anti-rotational guide to a housing of the delivery device; preventing rotation of the distal shaft with respect to the housing by slidably guiding the distal shaft along the anti-rotational guide, and extending the distal shaft and the anti-rotational guide linearly inside a cavity of the reservoir toward a distal end of the reservoir by rotating the proximal shaft wherein a distance of the extending of the distal shaft is greater than a distance of the extending of the anti-rotational guide.
According to some embodiments of the invention, the method further includes: driving the rotating of the proximal shaft with a motor of the drug delivery device.
According to some embodiments of the invention, the distal shaft is initially distanced proximally from the stopper and the extending is toward the stopper.
According to some embodiments of the invention, the distal shaft abuts against the stopper and further comprising driving the stopper inside the cavity toward the distal end of the reservoir by the extending of the distal shaft.
According to some embodiments of the invention, the method further comprises: attaching a linear stabilizer to the reservoir and inhibiting proximal movement of the proximal shaft with respect to the linear stabilizer.
According to some embodiments of the invention, the method further comprises: forming a cartridge including the reservoir, the stopper, the distal shaft, the anti-rotational guide, and the linear stabilizer and inserting the cartridge as a single unit into the drug delivery device.
According to some embodiments of the invention, the method further comprises: coupling the housing to the proximal shaft and inhibiting proximal movement of the proximal shaft with respect to the housing.
According to some embodiments of the invention, the preventing includes inserting a protrusion into a track.
According to some embodiments of the invention, the inserting includes elastically deforming at least one of the distal shaft and the anti-rotational guide.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
In the drawings:
The present invention, in some embodiments thereof, relates to a stopper driver for a drug delivery device and, more particularly, but not exclusively, to a telescoping stopper driver of a drug cartridge.
Overview
An aspect of some embodiments of the present invention relates to an anti-rotational guide for stopper driving assembly of a drug delivery device. Optionally, a distal shaft of the driver assembly is held rotationally stationary by the guide while being driven distally into the reservoir by relative rotation of a rotating proximal element. As the distal element progresses distally into the reservoir, the shaft may slide distally with respect to the guide. Additionally or alternatively, the guide and shaft may slide together distally into the reservoir. In some embodiment, the proximal element and the distal shaft may telescope when rotated in relation to one another. The proximal element may be held axially immobile with respect to the reservoir such that the telescoping of the proximal and distal elements forces the distal shaft into the reservoir.
Some embodiments may include a linear and/or a rotational stabilizer. For example a rotational stabilizer may be supported by a housing of the drug delivery device and/or a motor mount such that torque on the telescoping assembly is balanced against the anti-rotational guide and/or the motor and/or the housing of the delivery device. Optionally the torque will not be applied to the drug reservoir and/or the stopper and/or any part that is in contact with the drug.
In some embodiments, a linear force between the stopper and the driver assembly is balanced against the reservoir. Optionally the linear stress between the pushing assembly and the stopper is balanced with negligible or no external linear stresses on the drug delivery device and/or between the reservoir and the drug delivery device.
In some embodiments, the driver assembly may be attached to a drug reservoir to form a cartridge. The entire cartridge is optionally inserted as a unit into the drug delivery device. In some embodiments, the cartridge may meter out a drug while producing negligible or no external axial forces on the drug delivery device. For example, the cartridge assembly may include a linear stabilizer connecting the TSA to the drug reservoir. For example, the linear stabilizer may connect to the reservoir near a proximal opening of the reservoir and/or on a proximal flange thereof. Optionally, linear forces between a stopper and the TSA may be balanced by forces between the linear stabilizer and the reservoir. Optionally, the entire cartridge assembly is inserted into a proximal opening in a drug delivery device. Optionally when the cartridge is inserted into the proximal opening of the drug delivery device, a cannula pierces a septum creating a fluid path between the reservoir and the drug delivery device. For example the septum may be located on and/or near the distal end of the cartridge. Alternatively or additionally example the septum may be located on and/or near the distal portion of the drug delivery device.
In some embodiments a cartridge pushing assembly may be attached to a proximal opening of a reservoir without regard to the precise longitudinal position of a stopper in the reservoir. Optionally, after connecting the stopper pushing assembly to the reservoir, the TSA may be extended until the pushing assembly contacts the stopper. For example, the TSA may be extended before inserting the cartridge assembly into a drug device. Alternatively or additionally, The TSA may be extended after inserting the cartridge assembly into the drug delivery device.
In some embodiments, the stroke length of the TSA may be greater than the minimum length of the TSA. For example a TSA may have three telescoping shafts and/or three telescoping guides. For example a telescoping shaft may include an extension rod. Alternatively or additionally a TSA may have four telescoping shafts and/or four telescoping guides. Alternatively or additionally a TSA may have five telescoping shafts and/or five telescoping guides. For example a TSA may have a contracted configuration with length ranging between 0.8 and 1.6 cm and/or an extended configuration with length ranging between 2.0 to 4.0 cm. Optionally, the extended length of the TSA may range between 2.0 to 3.0 times the contracted length and/or between 3.0 to 5.0 times the contracted length.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
Cartridge Assembly
Referring now to the drawings,
In some embodiments, stopper driver assembly 150 may include a telescoping assembly (for example TSA 152). Optionally, TSA 152 includes a proximal shaft, for example a threaded drive shaft 110 and/or a threaded mid shaft 112 and/or a distal shaft, for example a threaded pushing shaft 114. Shafts 110, 112 and/or 114 may be coupled such that rotating drive shaft 110 with respect to pushing shaft 114 causes TSA 152 to lengthen and/or shorten. Optionally axial movement of drive shaft 110 is limited by linear stabilizer 106 such that rotating drive shaft 110 with respect to pushing shaft 114 causes pushing shaft 114 to move linearly with respect to linear stabilizer 106. Optionally, a coupling links pushing shaft 114 to anti-rotational guide 104. For example, rotation of pushing shaft 114 may be limited by anti-rotational guide 104 such that rotating drive shaft 110 with respect to anti-rotational guide 104 causes TSA 152 to lengthen and/or shorten. Alternatively or additionally, drive shaft 110 and/or pushing shaft 114 may be replaced by a nut and/or threaded disk and/or ring.
In some embodiments, linear stabilizer 106 may be attached to drug reservoir 120 and/or pushing shaft 114 may abut against stopper 140 such that extending TSA 152 moves stopper 140 axially with respect to reservoir 120. Axial back forces of stopper 140 with respect to reservoir 120 (for example due to friction between stopper and reservoir and/or due to flow resistance) are optionally balanced within cartridge 153 by a linear force between linear stabilizer 106 and reservoir 120.
In some embodiments, motor 108 may apply a torque to drive shaft 110. Optionally, anti-rotational guide 104 may be attached to drug reservoir 120 such that activating motor 108 moves pushing shaft 114 axially with respect to drive shaft 110. Friction between driving shaft 110 and pushing shaft 114 are optionally balanced by an anti-torque between motor 108 and anti-rotational guide 104 such that TSA 152 acts as a linear actuator putting a net linear force (and/or a negligible torque) on the parts of the device that are in contact with the drug (for example stopper 140 and/or reservoir 120).
In some embodiments, any or all of linear stabilizer 106, drive shaft 110, mid shaft 112, pushing shaft 114 and/or anti-rotational guide 104 may be partially and/or wholly located inside reservoir 120. Alternatively or additionally, any or all of linear stabilizer 106, drive shaft 110, mid shaft 112, pushing shaft 114 and/or anti-rotational guide 104 may be wholly or partially located outside reservoir 120 when TSA 152 is contracted and/or may move wholly or partially into reservoir 120 when TSA 152 expands.
In some embodiments, mid-shaft 112 and/or anti-rotational guide 104 may move axially. For example mid-shaft 112 and/or anti-rotational guide 104 may move into and/or out of reservoir 120. Optionally mid-shaft 112 may float. In the current disclosure, in some configurations (for example when TSA 152 is partially extended) the position of a floating part may be indeterminate. For example the part may move without changing the length of TSA 152. For example the order of movement of parts of TSA 152 may be not fixed. Optionally, driver shaft 110 may be an inner shaft and the pushing shaft 114 may be an outer shaft. Alternatively or additionally driver shaft 110 may be an outer shaft and the pushing shaft 114 may be an inner shaft. Any or all of the components of the current invention may be made of plastic and/or metal and/or another material.
Driving a Stopper
In some embodiments, the mid shaft may axially float. For example, when the TSA is extended the mid shaft may either extend linearly 212 with the pushing shaft and/or rotate 213 with the drive shaft. Optionally, for some lengths of the TSA, the position of the mid shaft may be indeterminate. For example, rotating 210 the drive shaft may, for example, extend 212 a mid-shaft into a reservoir (for example when the drive shaft rotates faster than the mid-shaft and/or by means of threading coupling the drive shaft to the mid shaft). Optionally, extending 212 the mid-shaft into the reservoir simultaneously extends 214 the pushing shaft into the reservoir. Alternatively or additionally, rotating 210 the drive shaft may rotate 213 the mid-shaft. Optionally, rotating 213 the mid-shaft extends 214 a pushing shaft into the reservoir (for example by means of threading coupling the drive shaft to the mid shaft). Rotation and/or extension of the mid shaft may occur concurrently and/or sequentially.
In some embodiments, the anti-rotational guide may axially float. For example, when the TSA is extended the anti-rotational guide may either extend 204 (for example moving axially with respect to and/or into the reservoir) along with the pushing shaft and/or the anti-rotational guide may remain stationary with respect to the reservoir and/or the pushing shaft may extend 214 axially with respect to the anti-rotational guide. Optionally, for some lengths of the TSA, the position of the anti-rotational guide may be indeterminate. In some embodiments, a pushing shaft may rotate while another element of the TSA is anti-rotationally stabilized (inhibited from rotating with respect for example to a drug delivery device housing and/or a motor).
Assembly and/or Installation of a Stopper Driver
In some embodiments a drug reservoir is supplied 320. Optionally the reservoir may be prefilled. For example, the reservoir may be filled using standard filling equipment. For example, the reservoir may have a cylindrical and/or tubular body of arbitrary cross section. For example the body may be in the form of a right circular cylinder. The reservoir optionally includes an internal cavity. Optionally, the internal cavity may be of arbitrary shape. For example, the internal cavity may have a smooth wall over at least half its length and/or over at least 90% of its length. For example the cavity of the reservoir may be substantially a right circular cylinder over at least half its length and/or over at least 90% of its length. For example the internal cavity may be coaxial with the outer walls of the reservoir over at least half its length and/or over at least 90% of its length. For example the cross section of the cavity may be uniform over at least half its length and/or over at least 90% of its length. Optionally the reservoir may include a distal opening. For example the distal end of the reservoir may include cannula for example a hypodermic needle and/or a mount for such. Alternatively or additionally the distal end of the reservoir and/or the distal opening may include a seal, for example a septum and/or sterile cover for example a needle cover. The proximal end of the reservoir may include a proximal opening. Optionally the proximal opening may be larger than the distal opening. For example the cross sectional area of the proximal opening may range between 5 to 50 times the cross sectional area of the distal opening and/or 50 to 500 times the cross sectional area of the distal opening. Optionally the cross sectional opening may be beveled and/or may smoothly connect to the internal cavity of the reservoir. Optionally, a stopper may be inserted into the proximal opening. Optionally the stopper may seal and/or preserve sterility of the contents of the reservoir. Optionally the position of the stopper may vary dependent on the volume of the contents of the reservoir. Optionally the proximal end of the reservoir may include a flange. For example the flange may extend from the between 20% to 100% of the perimeter of the reservoir. For example the flange may extend between 1 mm and 2 cm from the internal walls of the proximal opening. Optionally the reservoir may be made as a single integral unit for example of molded glass or plastic and/or cut and/or processed tubing.
In some embodiments a TSA is assembled in a simple manner. Optionally, assembly may be unidirectional. Unidirectional assembly may include, for example, insertion of all or most shafts from the same end of the TSA. Unidirectional assembly may include, for example, threading some most and/or all shafts in the same direction. Optionally, assembly may be accomplished without reversing orientation of the parts during assembly and/or adding without other complimentary work such as welding, riveting, plastic deformation etc.
In some embodiments, a series of shafts may be threaded together. For example for a leading end of an interior shaft may be inserted through a rear (distal) end of a more exterior shaft. For example a leading end of an interior shaft may be threaded into a more exterior shaft and/or a distal end of the more exterior shaft. As used herein, the term/phrase leading end means the end of a TSA from which the inner shaft projects in the extended state. As used herein, the term/phrase rear end means the end of a TSA from which the outer shaft projects in the extended state. As used herein, the term/phrase threading means screwing the more interior shaft towards the leading direction (in some embodiments threading is used to assemble and/or extend the TSA). As used herein, the term/phrase de-threading means screwing the more interior shaft towards the rear of the outer shaft (in some embodiments dethreading is used to contract the TSA). Alternatively or additionally, in some embodiments dethreading may be used to assemble and/or extend the TSA and/or threading may be used to contract the TSA. Optionally, the leading end of the most inner shaft may include a fastener and/or the rear end of the most external shaft may include a fastener.
In some embodiments of the invention a TSA resists disengagement and/or detaching of shafts upon extension. For example, an internal shaft of the TSA may include a flange and/or a step on its rear end. The flange may prevent disengagement from a more outer shaft. Alternatively or additional the flange may be replaced by a protrusion of a different geometry.
In some embodiments, a TSA may be simple assembled unidirectionally from a reverse extended position. The assembled TSA may optionally resist dis-assembly by extension.
In some embodiments a TSA is assembled from molded parts. In some embodiments, molding provides highly precise part geometries. Molded parts may optionally be assembled with minimal modifications during assembly. For example, the assembly of the TSA may be include minimal or no adhesion of parts, and/or changing of part geometries by heat and/or ultrasonic means and/or by force (for example by crimping). The molded parts may optionally include features to facilitate proper orientation. The molded parts may optionally include built in connectors and/or fasteners (for example snaps, latches, catches, hooks, clasps and the like). In some embodiments that parts may be molded of plastic. For example plastic may include low friction materials. Examples of such materials include a Polybutylene terephthalate (PBT) resin (for example CELANEX® resin available from TICONA) and/or a POM resin (for example Delrin® resin DuPont™).
In some embodiments an internal shaft may be molded in a single piece with the rear flange and/or projections. The flange and/or projection may optionally impede unintentional disengagement of the shaft. In some embodiments a part may be molded in a single piece with a fastener. In some embodiments a part may be molded in a single piece with a thread stopper and/or an interference element.
In some embodiments, some or all of the shafts of the assembly may optionally be supplied disassembled from an end cap. For example, the some or all of the shafts and/or end caps may include fasteners. The shafts may optionally be supplied with flanges inhibiting disassembly due to overextension. For example, an internal shaft may have a flange on a rear end. The flanges and/or fasteners may optionally be intrinsic. For example, the shafts and/or caps may be molded in a single piece with the fasteners and/or flanges.
In some embodiments, some or all of the shafts may be assembled together by reverse extension. For example, a leading end of an internal shaft may be inserted into a rear end of a more external shaft. For example, the internal shaft may be threaded from a disassembled (reverse extended) position through its contracted position out the leading end of a mating shaft to an extended position. In some embodiments, flanges which prevent the shafts from disattaching in the extended state may also prevent attaching the shafts from the extended state and threading them to the contracted state.
In some embodiments, a fastener may be supplied on a leading end of an inner shaft. Once the leading end of an inner shaft extends beyond the mating shaft, an end cap (for example a driver and/or an actuator) may be fastened to the fastener. Optionally an interference element may be supplied. For example the interference element may include a flange that blocks dethreading back to the reverse extended position and/or may include one or more protrusions that prevent thread lock resulting from collision between a shaft and an end cap.
Referring now to
In some embodiments, the leading end of the mid shaft along with the inner shaft may be threaded 312 into a rear end of a distal outer shaft (for example pushing shaft 414 of
In some embodiments, an actuator cap (for example distal cap 424 of
In some embodiments, an outer shaft may be connected 304 to a first anti-rotational guide (for example anti-rotational guide 404 of
In some embodiments, after assembly, the TSA may be contracted and/or rewound 328 (for example by dethreading) to a stop position. Optionally, the TSA may include one or more thread stoppers. For example, a thread stopper may include an interference element and/or a protrusion on a rotating shaft (for example mid shaft 412 and/or drive shaft 410) and/or on an end cap (for example actuator cap 424). One or more interference elements may meet at a predefined point in the contraction of the TSA and prevent further relative rotation. For example, the interference elements may prevent rotation in the dethreading direction of the inner shaft with respect to the outer shaft thereby inhibiting further contraction and/or thread lock (for example see interference elements 436 and 434 of
In some embodiments a stopper driver is attached to a drug reservoir to form a cartridge. For example, a linear stabilizer (for example stabilizer 402) may be attached to the reservoir (for example, connectors 421a may be attached to flange 421b as illustrated in
In some embodiments before inserting the cartridge into a drug delivery device, the TSA may be extended 314 to contact the stopper in the reservoir. Contacting the stopper with the TSA before engaging the TSA to the delivery device may make it easy to determine the volume of drug injected (based on the distance that the stopper has moved which may be proportional to the number of revolutions of the motor and/or drive shaft [for example the pitch of the threading on all of the shafts may be adjusted so that the ratio of revolutions to volume discharged is constant]). Alternatively or additionally, in some embodiments, the reservoir and/or the stopper driver and/or a complete cartridge may be inserted into a drug delivery device before the TSA has contacted the stopper. For example the motor of the drug delivery device may first drive the drive shaft to expand 314 the TSA until it contacts the stopper and then continue to drive the drive shaft to discharge the drug. Allowing the TSA to not contact the stopper until after insertion in the drug delivery device optionally simplifies production and or shipping of the cartridge. In some embodiments, the drug delivery device may deliver the entire content of the cartridge without tracking the quantity delivered. For example in some cases a cartridge may include exactly one dose. In some embodiments, the drug delivery device may include a sensor (for example a load sensor) that senses when the TSA is expanding 314 toward the stopper and/or when the TSA engages the stopper and/or when the TSA is pushing the stopper against a resistance (for example discharging the drug). Alternatively or additionally, the stopper may be placed into the reservoir in an exact position such that the TSA contacts the stopper exactly upon installation. For example it may be unnecessary to expand 314 the TSA after installation to contact the stopper.
In some embodiments, an anti-rotational guide is attached 322 to a housing of the drug delivery device. For example, in
A Stopper Driver with Sliding Sleeve Anti-Rotational Guide
Referring now to
In some embodiments a reservoir 420 may include a proximal opening 454, and/or a distal opening 456. Stopper 440 optionally seals the cavity of reservoir 420. Optionally the stopper may be placed at an arbitrary longitudinal position depending on, for example the volume of the drug distal to stopper 440 and/or space needed for the contracted stopper driver proximal to stopper 440.
In some embodiments, reservoir 420 may include a distal opening 456 and/or a proximal opening 454. For example, proximal opening 454 may be large enough to insert stopper 440. Optionally, distal opening may be configured with a neck and/or a mount for a needle and/or a septum.
In some embodiments, stopper driver 450 includes a TSA 452. TSA 452 is optionally assembled from the reverse expanded state (e.g. as illustrated in
In some embodiments, TSA 452 is engaged to an anti-rotational guide and/or a transmission element. For example, a coupling including a projection 415a engaged to a track 415b may link pushing shaft 414 to an anti-rotational guide 404. Anti-rotational guide is optionally engaged to a stabilizer 402. For example, a projection 405a of anti-rotational guide 404 may be engaged to a track 405b (for example see
In some embodiments, once TSA 452 is connected its anti-rotational guides (for example anti-rotational guide 404 and/or stabilizer 402) the guides are slid together and/or collapsed such that the proximal end of drive shaft 410 projects out of a proximal opening 403 in stabilizer 402 and/or until a coupler (for example a shoulder bearing 406) of drive shaft 410 rests against stabilizer 402. Optionally, drive shaft 410 rotates freely inside of opening 403. Optionally the transmission element includes for example a cartridge gear 426. The transmission element is optionally engaged to the projecting proximal portion of drive shaft 410. For example, a non-rotational fitting 432a may be inserted through a slot and/or a receptor 432b of cartridge gear 426 such that drive shaft 410 is firmly engaged and/or aligned to gear 426 and/or rotates with gear 426. Optionally a fastener and/or a snap element prevent disassembly of stopper driver 450. For example an end cap 438 may snap to a retainer 437 which may hold to a fastener 430 on the proximal end of drive shaft 410 in
Referring now to
In some embodiments a shaft may include a member to prevent disengagement of the shaft during over threading and/or over extension of the TSA. For example drive shaft 410 includes a rear flange 482 and mid shaft 412 includes a rear flange 484. When shaft 410 reaches full extension, flange 482 optionally contacts interior threads 411b of mid shaft 412 preventing further extension. When shaft 412 reaches full extension, flange 484 optionally contacts interior threads 413b of pushing shaft 414 preventing further extension. Alternatively or additionally an element to prevent disengagement of shafts due to over extension (for example flange 482 and/or 484). Optionally the element preventing over extension may include an interference element and/or a protrusion and/or another element of any geometry for example an annular element.
In some embodiments, a linear stabilizer will block movement of a drive shaft in a proximal direction. For example, shoulder bearing 406 is supported against stabilizer 402. Optionally, drive shaft 410 can rotate with respect to stabilizer 402 around the longitudinal axis of stopper driver 450 but is inhibited from moving axially in a proximal direction with respect to stabilizer 402.
In some embodiments, Cartridge 453 is inserted as a single element into a drug delivery device. Optionally, when stopper driver 450 is installed to cartridge 453 in a contracted state, a large portion of driver 450 (for example ranging between 50% to 75% and/or ranging between 75% to 90% and/or ranging between 90% to 100%) is positioned inside reservoir 420. Alternatively or additionally most or all of the stopper driver may be on the outside of the reservoir when the driver is in a contracted state and/or when the driver is attached to the reservoir.
In some embodiments, linear stabilizer 402 (as explained above) is also an anti-rotational stabilizer 402. Optionally, stabilizer 402 connects directly to device 422 to compensate for torque applied by a motor 408 to cartridge gear 426 without applying significant torque to reservoir 420. For example, connectors 421a of stabilizer 402 fit into slots 421c in drug delivery device 422. Slots 421c prevent stabilizer 402 from rotating with respect to device 422. Slots 421c are angled to lead connectors 421a and/or rotationally align cartridge 453. For example cartridge 453 may be inserted into device 422 without require angular alignment by the operator. Alternatively or additionally a cartridge may have a specific insertion alignment. In some embodiments, a linear stabilizer may be separate from an anti-rotational stabilizer.
A Stopper Driver with Sliding Post Anti-Rotational Guide
A Stopper Driver with Anti-Rotational Guide Stabilized by the Device Housing
Exemplary Dimensions of a Drug Delivery Device
In some embodiments the payload of a reservoir (for example a syringe) may include, for example between 0.5 and 3 ml and/or between 3 and 6 ml and/or between 6 and 10 ml and/or between 10 and 15 ml of a drug and/or more. In some embodiments, the injector may discharge the entire payload as a single dose. A drug delivery device may include, for example, a pen injector and/or a patch injector, and/or an internally powered driver to drive the stopper and/or discharge the payload. The reservoir of the injector may be oriented parallel to the skin of a subject and/or perpendicular to the skin and/or at an angle between parallel and perpendicular, for example between 60 to 90 degrees and/or between 30 to 60 degrees and/or between 0 to 30 degrees. For the sake of this application an internally powered injector driver may be defined as a drive mechanism powered by energy stored at least temporarily within the injector. Power may be stored in a power supply, for instance as chemical potential (for example a chemical that produces an expanding gas and/or a battery) and/or mechanical potential (for example stored in an elastic member and/or a spring and/or a pressurized gas). For example the driver may be designed to discharge the payload over a time period ranging between 20 and 120 seconds and/or between 120 and 600 seconds and/or between 600 and 7200 seconds and/or longer. In some embodiments, discharge may be driven by a driver. An internally powered driver may be powered by various mechanisms including for example a motor (including for example a DC motor, an actuator, a brushless motor) and/or a transmission including for example a telescoping assembly and/or a threaded element and/or a gear and/or a coupling and/or an elastic mechanism (for example a spring and/or a rubber band) and/or an expanding gas and/or a hydraulic actuator).
A drug delivery device in accordance with some embodiments of the current invention may include reservoir. For example a reservoir may include a medicine container and/or a standard type syringe. Optionally a standard type syringe may be preloaded with medicine using standard equipment and/or in an aseptic room. A preloaded standard type syringe may optionally include a proximal opening. A stopper may optionally seal the proximal opening and/or protect the sterility of the contents of the syringe. A sterile needle (for example a hollow needle) may optionally be connected to the syringe barrel. For example, the hollow of the needle may be in fluid communication with the interior of the barrel. The needle may optionally be rigidly attached to the distal end of the barrel. The sterility of all and/or part of the needle may for example be protected by a sterile cover. The sterile cover may remain on the needle when the syringe is supplied and/or installed into an injector. For example, the medicine container may optionally include a cylindrical barrel rigidly attached to a needle. Optionally, the long axes of the needle and barrel of the syringe may be parallel and/or coaxial. Optionally, the needle may be mounted on the distal end of the barrel. Optionally the needle point may be pointing in the distal direction. In some embodiments a stopper may slide axially along the inside of the barrel to discharge a medicine payload. For example, the medicine may be discharged through the hollow needle.
In some embodiments, a TSA may produce a force ranging for example between 0.02 to 0.2 N and/or between 0.2 and 0.5 N and/or between 0.5 to 5 N and/or between 5 to 60 N and/or between 60 to 90 N. For example the force required to inject the drug may depend on the injection rate and/or the viscosity of the drug and/or the syringe geometry and/or the needle dimensions.
In some embodiments, the stress to inject a medicine may include a torque. For example, injection of medicine may be driven by a stopper. The stopper may optionally be driven by a threaded assembly, for example a threaded screw and/or teeth and/or a telescoping assembly. Optionally the pitch of the teeth and/or an associated screw may range for example between 0.5 and 2 mm. The diameter of the screw may range for example between 3 and 15 mm. The torque to power injection may range for example between 0.2 and 1.0 N*cm.
During injection, the linear movement of a stopper may range for example between 5-40 mm and/or between 40-50 mm. The length of movement of the stopper may vary for example with the volume of medicine to be injected that may range for example between 0.5 to 3 ml and/or between 3 to 10 ml.
It is expected that during the life of a patent maturing from this application many relevant technologies will be developed and the scope of the terms is intended to include all such new technologies a priori.
As used herein the term “about” refers to ±5%.
The terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.
The term “consisting of” means “including and limited to”.
The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.
Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
Number | Name | Date | Kind |
---|---|---|---|
232432 | Alison | Sep 1880 | A |
1795630 | Wilson | Mar 1931 | A |
2677373 | Barradas | May 1954 | A |
2702547 | Glass | Feb 1955 | A |
2860635 | Wilburn | Nov 1958 | A |
3203269 | Perrine | Aug 1965 | A |
3212685 | Richard et al. | Oct 1965 | A |
3623474 | Heilman et al. | Nov 1971 | A |
3794028 | Mueller et al. | Feb 1974 | A |
3994295 | Wulff | Nov 1976 | A |
4195636 | Behnke | Apr 1980 | A |
4218724 | Kaufman | Aug 1980 | A |
4254768 | Ty | Mar 1981 | A |
4273122 | Whitney et al. | Jun 1981 | A |
4300554 | Hessberg et al. | Nov 1981 | A |
4403987 | Gottinger | Sep 1983 | A |
4435173 | Siposs et al. | Mar 1984 | A |
4465478 | Sabelman et al. | Aug 1984 | A |
4502488 | Degironimo et al. | Mar 1985 | A |
4504263 | Steuer et al. | Mar 1985 | A |
4564054 | Gustaysson | Jan 1986 | A |
4565543 | Bekkering et al. | Jan 1986 | A |
4585439 | Michel | Apr 1986 | A |
4599082 | Grimard | Jul 1986 | A |
4601702 | Hudson | Jul 1986 | A |
4664654 | Strauss | May 1987 | A |
4685903 | Cable et al. | Aug 1987 | A |
4698055 | Sealfon | Oct 1987 | A |
4735311 | Lowe et al. | Apr 1988 | A |
4810215 | Kaneko | Mar 1989 | A |
4850966 | Grau et al. | Jul 1989 | A |
4867743 | Vaillancourt | Sep 1989 | A |
4882575 | Kawahara | Nov 1989 | A |
4886499 | Cirelli et al. | Dec 1989 | A |
4892521 | Laico et al. | Jan 1990 | A |
4919596 | Slate et al. | Apr 1990 | A |
4929241 | Kulli | May 1990 | A |
4950246 | Muller | Aug 1990 | A |
4964866 | Szwarc | Oct 1990 | A |
5051109 | Simon | Sep 1991 | A |
D322671 | Szwarc | Dec 1991 | S |
5109850 | Blanco et al. | May 1992 | A |
5112317 | Michel | May 1992 | A |
5131816 | Brown et al. | Jul 1992 | A |
5190521 | Hubbard et al. | Mar 1993 | A |
5254096 | Rondelet et al. | Oct 1993 | A |
5300045 | Plassche, Jr. | Apr 1994 | A |
5318522 | D'Antonio | Jun 1994 | A |
5342313 | Campbell et al. | Aug 1994 | A |
5348544 | Sweeney et al. | Sep 1994 | A |
5366498 | Brannan et al. | Nov 1994 | A |
5383865 | Michel | Jan 1995 | A |
5478315 | Brothers et al. | Dec 1995 | A |
5482446 | Williamson et al. | Jan 1996 | A |
5496274 | Graves et al. | Mar 1996 | A |
5501665 | Jhuboo et al. | Mar 1996 | A |
5505709 | Funderburk et al. | Apr 1996 | A |
5562624 | Righi et al. | Oct 1996 | A |
5562686 | Sauer et al. | Oct 1996 | A |
5593390 | Castellano et al. | Jan 1997 | A |
5616132 | Newman | Apr 1997 | A |
5624400 | Firth et al. | Apr 1997 | A |
5637095 | Nason et al. | Jun 1997 | A |
5643218 | Lynn et al. | Jul 1997 | A |
5645530 | Boukhny et al. | Jul 1997 | A |
5645955 | Maglica | Jul 1997 | A |
5647853 | Feldmann et al. | Jul 1997 | A |
5658256 | Shields | Aug 1997 | A |
5662678 | Macklin | Sep 1997 | A |
5672160 | Osterlind et al. | Sep 1997 | A |
5690618 | Smith et al. | Nov 1997 | A |
5728075 | Levander | Mar 1998 | A |
D393314 | Meisner et al. | Apr 1998 | S |
5766186 | Faraz et al. | Jun 1998 | A |
5795675 | Maglica | Aug 1998 | A |
5800420 | Gross et al. | Sep 1998 | A |
5807375 | Gross et al. | Sep 1998 | A |
5810784 | Tamaro | Sep 1998 | A |
5814020 | Gross | Sep 1998 | A |
5830187 | Kriesel et al. | Nov 1998 | A |
5836920 | Robertson | Nov 1998 | A |
5848991 | Gross et al. | Dec 1998 | A |
5851197 | Marano et al. | Dec 1998 | A |
5858001 | Tsals et al. | Jan 1999 | A |
5858008 | Capaccio | Jan 1999 | A |
5868710 | Battiato et al. | Feb 1999 | A |
5893842 | Imbert | Apr 1999 | A |
5894015 | Rechtin | Apr 1999 | A |
5919167 | Mulhauser et al. | Jul 1999 | A |
5926596 | Edwards et al. | Jul 1999 | A |
5931814 | Alex et al. | Aug 1999 | A |
5941850 | Shah et al. | Aug 1999 | A |
5944699 | Barrelle et al. | Aug 1999 | A |
5948392 | Haslwanter et al. | Sep 1999 | A |
5954697 | Srisathapat et al. | Sep 1999 | A |
5957895 | Sage et al. | Sep 1999 | A |
5968011 | Larsen et al. | Oct 1999 | A |
5989221 | Hjertman | Nov 1999 | A |
5993423 | Choi | Nov 1999 | A |
6004297 | Steenfeldt-Jensen et al. | Dec 1999 | A |
6033245 | Yamkovoy | Mar 2000 | A |
6033377 | Rasmussen et al. | Mar 2000 | A |
6045533 | Kriesel et al. | Apr 2000 | A |
6064797 | Crittendon et al. | May 2000 | A |
6074369 | Sage et al. | Jun 2000 | A |
6186982 | Gross et al. | Feb 2001 | B1 |
6200289 | Hochman et al. | Mar 2001 | B1 |
6200296 | Dibiasi et al. | Mar 2001 | B1 |
6224569 | Brimhall | May 2001 | B1 |
6248093 | Moberg | Jun 2001 | B1 |
6270481 | Mason et al. | Aug 2001 | B1 |
6277095 | Kriesel et al. | Aug 2001 | B1 |
6277098 | Klitmose et al. | Aug 2001 | B1 |
6277099 | Strowe et al. | Aug 2001 | B1 |
6287283 | Ljunggreen et al. | Sep 2001 | B1 |
6293925 | Safabash et al. | Sep 2001 | B1 |
6302633 | Poe | Oct 2001 | B1 |
6336729 | Pavelle et al. | Jan 2002 | B1 |
6345968 | Shupe | Feb 2002 | B1 |
6377848 | Garde et al. | Apr 2002 | B1 |
6391005 | Lum et al. | May 2002 | B1 |
6423029 | Elsberry | Jul 2002 | B1 |
D465026 | May et al. | Oct 2002 | S |
6458102 | Mann et al. | Oct 2002 | B1 |
6485461 | Mason et al. | Nov 2002 | B1 |
6485465 | Moberg et al. | Nov 2002 | B2 |
6500150 | Gross et al. | Dec 2002 | B1 |
6503231 | Prausnitz et al. | Jan 2003 | B1 |
6511336 | Turek et al. | Jan 2003 | B1 |
6517517 | Farrugia et al. | Feb 2003 | B1 |
D471274 | Diaz et al. | Mar 2003 | S |
D471983 | Hippolyte et al. | Mar 2003 | S |
6554800 | Nezhadian et al. | Apr 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6565541 | Sharp | May 2003 | B2 |
6589229 | Connelly et al. | Jul 2003 | B1 |
6595956 | Gross et al. | Jul 2003 | B1 |
6595960 | West et al. | Jul 2003 | B2 |
6645181 | Lavi et al. | Nov 2003 | B1 |
6652482 | Hochman | Nov 2003 | B2 |
6656158 | Mahoney et al. | Dec 2003 | B2 |
6656159 | Flaherty | Dec 2003 | B2 |
6659980 | Moberg et al. | Dec 2003 | B2 |
6673033 | Sciulli et al. | Jan 2004 | B1 |
6679862 | Diaz et al. | Jan 2004 | B2 |
6689118 | Alchas et al. | Feb 2004 | B2 |
6699218 | Flaherty et al. | Mar 2004 | B2 |
6722916 | Buccinna et al. | Apr 2004 | B2 |
6743211 | Prausnitz et al. | Jun 2004 | B1 |
6749587 | Flaherty | Jun 2004 | B2 |
6752787 | Causey, III et al. | Jun 2004 | B1 |
6768425 | Flaherty et al. | Jul 2004 | B2 |
6786890 | Preuthun et al. | Sep 2004 | B2 |
6800071 | McConnell et al. | Oct 2004 | B1 |
6805687 | Dextradeur et al. | Oct 2004 | B2 |
6824529 | Gross et al. | Nov 2004 | B2 |
6843782 | Gross et al. | Jan 2005 | B2 |
6854620 | Ramey | Feb 2005 | B2 |
6905298 | Haring | Jun 2005 | B1 |
6908452 | Diaz et al. | Jun 2005 | B2 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
6997727 | Legrady et al. | Feb 2006 | B1 |
7001360 | Veasey et al. | Feb 2006 | B2 |
7033338 | Vilks et al. | Apr 2006 | B2 |
7034223 | Fan et al. | Apr 2006 | B2 |
7048715 | Diaz et al. | May 2006 | B2 |
7060054 | Nissels | Jun 2006 | B2 |
7060059 | Keith et al. | Jun 2006 | B2 |
7066909 | Peter et al. | Jun 2006 | B1 |
7097637 | Triplett et al. | Aug 2006 | B2 |
7128727 | Flaherty et al. | Oct 2006 | B2 |
7144384 | Gorman et al. | Dec 2006 | B2 |
D544092 | Lewis | Jun 2007 | S |
7225694 | Said | Jun 2007 | B2 |
7247149 | Beyerlein | Jul 2007 | B2 |
7250037 | Shermer et al. | Jul 2007 | B2 |
7267669 | Staunton et al. | Sep 2007 | B2 |
7291132 | DeRuntz et al. | Nov 2007 | B2 |
7291159 | Schmelzeisen-Redeker et al. | Nov 2007 | B2 |
7303549 | Flaherty et al. | Dec 2007 | B2 |
7344385 | Chen | Mar 2008 | B2 |
7364570 | Gerondale et al. | Apr 2008 | B2 |
7390314 | Stutz, Jr. et al. | Jun 2008 | B2 |
7407493 | Cane′ | Aug 2008 | B2 |
D578210 | Muta et al. | Oct 2008 | S |
7442186 | Blomquist | Oct 2008 | B2 |
7455663 | Bikovsky | Nov 2008 | B2 |
7465290 | Reilly | Dec 2008 | B2 |
7488181 | van Haaster | Feb 2009 | B2 |
7497842 | Diaz et al. | Mar 2009 | B2 |
7501587 | English | Mar 2009 | B2 |
7503786 | Kato et al. | Mar 2009 | B2 |
7530964 | Lavi et al. | May 2009 | B2 |
7540858 | DiBiasi | Jun 2009 | B2 |
7547281 | Hayes et al. | Jun 2009 | B2 |
7565208 | Harris et al. | Jul 2009 | B2 |
7569050 | Moberg et al. | Aug 2009 | B2 |
D600341 | Loerwald | Sep 2009 | S |
7585287 | Bresina et al. | Sep 2009 | B2 |
7588559 | Aravena et al. | Sep 2009 | B2 |
7589974 | Grady et al. | Sep 2009 | B2 |
D602155 | Foley et al. | Oct 2009 | S |
D602586 | Foley et al. | Oct 2009 | S |
D604835 | Conley | Nov 2009 | S |
7628770 | Ethelfeld | Dec 2009 | B2 |
7628772 | McConnell et al. | Dec 2009 | B2 |
7628782 | Adair et al. | Dec 2009 | B2 |
7637891 | Wall | Dec 2009 | B2 |
7637899 | Woolston et al. | Dec 2009 | B2 |
7641649 | Moberg et al. | Jan 2010 | B2 |
7660627 | McNichols et al. | Feb 2010 | B2 |
7678079 | Shermer et al. | Mar 2010 | B2 |
7682338 | Griffin | Mar 2010 | B2 |
7686787 | Moberg et al. | Mar 2010 | B2 |
7699829 | Harris et al. | Apr 2010 | B2 |
7699833 | Moberg et al. | Apr 2010 | B2 |
7704088 | Sakamoto | Apr 2010 | B2 |
7704227 | Moberg et al. | Apr 2010 | B2 |
7704229 | Moberg et al. | Apr 2010 | B2 |
7704231 | Pongpairochana et al. | Apr 2010 | B2 |
7708717 | Estes et al. | May 2010 | B2 |
7713238 | Mernoe | May 2010 | B2 |
7713240 | Istoc et al. | May 2010 | B2 |
7717903 | Estes et al. | May 2010 | B2 |
7717913 | Novak et al. | May 2010 | B2 |
7722574 | Toman et al. | May 2010 | B2 |
7736344 | Moberg et al. | Jun 2010 | B2 |
7744589 | Mounce et al. | Jun 2010 | B2 |
7749194 | Edwards et al. | Jul 2010 | B2 |
7766867 | Lynch et al. | Aug 2010 | B2 |
7776030 | Estes et al. | Aug 2010 | B2 |
7780637 | Jerde et al. | Aug 2010 | B2 |
7789857 | Moberg et al. | Sep 2010 | B2 |
7794426 | Briones et al. | Sep 2010 | B2 |
7801599 | Young et al. | Sep 2010 | B2 |
7806868 | De Polo et al. | Oct 2010 | B2 |
7828528 | Estes et al. | Nov 2010 | B2 |
7837659 | Bush, Jr. et al. | Nov 2010 | B2 |
7846132 | Gravesen et al. | Dec 2010 | B2 |
7854723 | Hwang et al. | Dec 2010 | B2 |
7857131 | Vedrine | Dec 2010 | B2 |
7879025 | Jacobson et al. | Feb 2011 | B2 |
7918825 | O'Connor et al. | Apr 2011 | B2 |
7935104 | Yodfat et al. | May 2011 | B2 |
7935105 | Miller et al. | May 2011 | B2 |
7938803 | Mernoe et al. | May 2011 | B2 |
7955305 | Moberg et al. | Jun 2011 | B2 |
7967784 | Pongpairochana et al. | Jun 2011 | B2 |
7967795 | Cabiri | Jun 2011 | B1 |
7981105 | Adair et al. | Jul 2011 | B2 |
7988683 | Adair et al. | Aug 2011 | B2 |
7993300 | Nyholm et al. | Aug 2011 | B2 |
7993301 | Boyd et al. | Aug 2011 | B2 |
7998111 | Moberg et al. | Aug 2011 | B2 |
8021357 | Tanaka et al. | Sep 2011 | B2 |
8025658 | Chong et al. | Sep 2011 | B2 |
8029469 | Ethelfeld | Oct 2011 | B2 |
8034019 | Nair et al. | Oct 2011 | B2 |
8038666 | Triplett et al. | Oct 2011 | B2 |
8057431 | Woehr et al. | Nov 2011 | B2 |
8057436 | Causey et al. | Nov 2011 | B2 |
8062253 | Nielsen et al. | Nov 2011 | B2 |
8066694 | Wagener | Nov 2011 | B2 |
D650079 | Presta et al. | Dec 2011 | S |
D650903 | Kosinski et al. | Dec 2011 | S |
8086306 | Katzman et al. | Dec 2011 | B2 |
D652503 | Cameron et al. | Jan 2012 | S |
8105279 | Mernoe et al. | Jan 2012 | B2 |
8105293 | Pickhard | Jan 2012 | B2 |
8114046 | Covino et al. | Feb 2012 | B2 |
8114064 | Alferness et al. | Feb 2012 | B2 |
8114066 | Naef et al. | Feb 2012 | B2 |
D657462 | Siroky | Apr 2012 | S |
8147446 | Yodfat et al. | Apr 2012 | B2 |
8152764 | Istoc et al. | Apr 2012 | B2 |
8152770 | Reid | Apr 2012 | B2 |
8152779 | Cabiri | Apr 2012 | B2 |
8152793 | Keinanen et al. | Apr 2012 | B2 |
8157693 | Waksmundzki | Apr 2012 | B2 |
8157769 | Cabiri | Apr 2012 | B2 |
8162674 | Cho et al. | Apr 2012 | B2 |
8162923 | Adams et al. | Apr 2012 | B2 |
8167841 | Teisen-Simony et al. | May 2012 | B2 |
8172591 | Wertz | May 2012 | B2 |
8172804 | Bikovsky | May 2012 | B2 |
8177749 | Slate et al. | May 2012 | B2 |
8182462 | Istoc et al. | May 2012 | B2 |
8197444 | Bazargan et al. | Jun 2012 | B1 |
8206351 | Sugimoto et al. | Jun 2012 | B2 |
8221356 | Enggaard et al. | Jul 2012 | B2 |
8267921 | Yodfat et al. | Sep 2012 | B2 |
8287520 | Drew et al. | Oct 2012 | B2 |
8292647 | McGrath et al. | Oct 2012 | B1 |
8308679 | Hanson et al. | Nov 2012 | B2 |
8323250 | Chong et al. | Dec 2012 | B2 |
8348898 | Cabiri | Jan 2013 | B2 |
8372039 | Mernoe et al. | Feb 2013 | B2 |
8373421 | Lindegger et al. | Feb 2013 | B2 |
8409142 | Causey et al. | Apr 2013 | B2 |
8414557 | Istoc et al. | Apr 2013 | B2 |
8425468 | Weston | Apr 2013 | B2 |
8430847 | Mernoe et al. | Apr 2013 | B2 |
8465455 | Cabiri | Jun 2013 | B2 |
8469942 | Kow et al. | Jun 2013 | B2 |
8474332 | Bente, IV et al. | Jul 2013 | B2 |
8475408 | Mernoe et al. | Jul 2013 | B2 |
8479595 | Vazquez et al. | Jul 2013 | B2 |
8495918 | Bazargan et al. | Jul 2013 | B2 |
8496862 | Zelkovich et al. | Jul 2013 | B2 |
8512287 | Cindrich et al. | Aug 2013 | B2 |
8512295 | Evans et al. | Aug 2013 | B2 |
8517987 | Istoc et al. | Aug 2013 | B2 |
8523803 | Favreau | Sep 2013 | B1 |
8551046 | Causey et al. | Oct 2013 | B2 |
8556856 | Bazargan et al. | Oct 2013 | B2 |
8562364 | Lin et al. | Oct 2013 | B2 |
8574216 | Istoc et al. | Nov 2013 | B2 |
8603026 | Favreau | Dec 2013 | B2 |
8603027 | Favreau | Dec 2013 | B2 |
8622966 | Causey et al. | Jan 2014 | B2 |
8628510 | Bazargan et al. | Jan 2014 | B2 |
8674288 | Hanson et al. | Mar 2014 | B2 |
8679060 | Mernoe et al. | Mar 2014 | B2 |
8690855 | Alderete, Jr. et al. | Apr 2014 | B2 |
8708961 | Field et al. | Apr 2014 | B2 |
8751237 | Kubota | Jun 2014 | B2 |
8753326 | Chong et al. | Jun 2014 | B2 |
8753331 | Murphy | Jun 2014 | B2 |
8764707 | Moberg et al. | Jul 2014 | B2 |
8764723 | Chong et al. | Jul 2014 | B2 |
8771222 | Kanderian, Jr. et al. | Jul 2014 | B2 |
8777896 | Starkweather et al. | Jul 2014 | B2 |
8777924 | Kanderian, Jr. et al. | Jul 2014 | B2 |
8777925 | Patton | Jul 2014 | B2 |
8784369 | Starkweather et al. | Jul 2014 | B2 |
8784370 | Lebel et al. | Jul 2014 | B2 |
8790295 | Sigg et al. | Jul 2014 | B1 |
8795224 | Starkweather et al. | Aug 2014 | B2 |
8795231 | Chong et al. | Aug 2014 | B2 |
8795260 | Drew | Aug 2014 | B2 |
8801668 | Ali et al. | Aug 2014 | B2 |
8801679 | Iio et al. | Aug 2014 | B2 |
8810394 | Kalpin | Aug 2014 | B2 |
8814379 | Griffiths et al. | Aug 2014 | B2 |
8915882 | Cabiri | Dec 2014 | B2 |
8920374 | Bokelman et al. | Dec 2014 | B2 |
8979802 | Woehr | Mar 2015 | B2 |
9011164 | Filman et al. | Apr 2015 | B2 |
9061104 | Daniel | Jun 2015 | B2 |
9061110 | Avery et al. | Jun 2015 | B2 |
9072827 | Cabiri | Jul 2015 | B2 |
9089475 | Fangrow | Jul 2015 | B2 |
9089641 | Kavazov | Jul 2015 | B2 |
9149575 | Cabiri | Oct 2015 | B2 |
9173997 | Gross et al. | Nov 2015 | B2 |
D747799 | Norton et al. | Jan 2016 | S |
9259532 | Cabiri | Feb 2016 | B2 |
9314569 | Causey et al. | Apr 2016 | B2 |
9345836 | Cabin et al. | May 2016 | B2 |
9350634 | Fadell | May 2016 | B2 |
9393365 | Cabiri | Jul 2016 | B2 |
9421323 | Cabiri et al. | Aug 2016 | B2 |
9452261 | Alon | Sep 2016 | B2 |
9522234 | Cabiri | Dec 2016 | B2 |
9539388 | Causey et al. | Jan 2017 | B2 |
9572926 | Cabiri | Feb 2017 | B2 |
9656019 | Cabiri et al. | May 2017 | B2 |
9782545 | Gross et al. | Oct 2017 | B2 |
20010018937 | Nemoto | Sep 2001 | A1 |
20010025168 | Gross et al. | Sep 2001 | A1 |
20010034502 | Moberg et al. | Oct 2001 | A1 |
20010041869 | Causey et al. | Nov 2001 | A1 |
20020010423 | Gross et al. | Jan 2002 | A1 |
20020016569 | Critchlow et al. | Feb 2002 | A1 |
20020029018 | Jeffrey | Mar 2002 | A1 |
20020040208 | Flaherty et al. | Apr 2002 | A1 |
20020055711 | Lavi et al. | May 2002 | A1 |
20020065488 | Suzuki et al. | May 2002 | A1 |
20020107487 | Preuthun | Aug 2002 | A1 |
20020123740 | Flaherty et al. | Sep 2002 | A1 |
20020151855 | Douglas et al. | Oct 2002 | A1 |
20020161332 | Ramey | Oct 2002 | A1 |
20020169215 | Meng | Nov 2002 | A1 |
20030009133 | Ramey | Jan 2003 | A1 |
20030014018 | Giambattista et al. | Jan 2003 | A1 |
20030125671 | Aramata et al. | Jul 2003 | A1 |
20030135159 | Daily et al. | Jul 2003 | A1 |
20030160683 | Blomquist | Aug 2003 | A1 |
20030171717 | Farrugia et al. | Sep 2003 | A1 |
20030216683 | Shekalim | Nov 2003 | A1 |
20040000818 | Preuthun | Jan 2004 | A1 |
20040010207 | Flaherty et al. | Jan 2004 | A1 |
20040049160 | Hsieh et al. | Mar 2004 | A1 |
20040049161 | Shearn | Mar 2004 | A1 |
20040082911 | Tiu et al. | Apr 2004 | A1 |
20040092873 | Moberg | May 2004 | A1 |
20040116866 | Gorman et al. | Jun 2004 | A1 |
20040127857 | Shemesh et al. | Jul 2004 | A1 |
20040158172 | Hancock | Aug 2004 | A1 |
20040186419 | Cho | Sep 2004 | A1 |
20040186441 | Graf et al. | Sep 2004 | A1 |
20040210196 | Bush, Jr. et al. | Oct 2004 | A1 |
20040260233 | Garibotto et al. | Dec 2004 | A1 |
20050033234 | Sadowski et al. | Feb 2005 | A1 |
20050038391 | Wittland et al. | Feb 2005 | A1 |
20050065466 | Vedrine | Mar 2005 | A1 |
20050065472 | Cindrich et al. | Mar 2005 | A1 |
20050071487 | Lu et al. | Mar 2005 | A1 |
20050113761 | Faust et al. | May 2005 | A1 |
20050124940 | Martin et al. | Jun 2005 | A1 |
20050159706 | Wilkinson et al. | Jul 2005 | A1 |
20050171476 | Judson et al. | Aug 2005 | A1 |
20050171512 | Flaherty | Aug 2005 | A1 |
20050177136 | Miller | Aug 2005 | A1 |
20050197650 | Sugimoto et al. | Sep 2005 | A1 |
20050203461 | Flaherty et al. | Sep 2005 | A1 |
20050238507 | Dilanni et al. | Oct 2005 | A1 |
20050283114 | Bresina et al. | Dec 2005 | A1 |
20060013716 | Nason et al. | Jan 2006 | A1 |
20060030816 | Zubry | Feb 2006 | A1 |
20060095014 | Ethelfeld | May 2006 | A1 |
20060122577 | Poulsen et al. | Jun 2006 | A1 |
20060124269 | Miyazaki et al. | Jun 2006 | A1 |
20060173406 | Hayes et al. | Aug 2006 | A1 |
20060173439 | Thorne et al. | Aug 2006 | A1 |
20060195029 | Shults et al. | Aug 2006 | A1 |
20060206054 | Shekalim | Sep 2006 | A1 |
20060211982 | Prestrelski et al. | Sep 2006 | A1 |
20060229569 | Lavi et al. | Oct 2006 | A1 |
20060264888 | Moberg et al. | Nov 2006 | A1 |
20060264889 | Moberg et al. | Nov 2006 | A1 |
20060264890 | Moberg et al. | Nov 2006 | A1 |
20060264894 | Moberg et al. | Nov 2006 | A1 |
20060270987 | Peter | Nov 2006 | A1 |
20060283465 | Nickel et al. | Dec 2006 | A1 |
20060293722 | Slatkine et al. | Dec 2006 | A1 |
20070021733 | Hansen et al. | Jan 2007 | A1 |
20070025879 | Vandergaw | Feb 2007 | A1 |
20070049865 | Radmer et al. | Mar 2007 | A1 |
20070073228 | Mernoe et al. | Mar 2007 | A1 |
20070118405 | Campbell et al. | May 2007 | A1 |
20070167912 | Causey et al. | Jul 2007 | A1 |
20070179444 | Causey et al. | Aug 2007 | A1 |
20070185449 | Mernoe | Aug 2007 | A1 |
20070197954 | Keenan | Aug 2007 | A1 |
20070197968 | Pongpairochana et al. | Aug 2007 | A1 |
20070203454 | Shermer et al. | Aug 2007 | A1 |
20070233038 | Pruitt et al. | Oct 2007 | A1 |
20070282269 | Carter et al. | Dec 2007 | A1 |
20080021439 | Brittingham et al. | Jan 2008 | A1 |
20080033367 | Haury et al. | Feb 2008 | A1 |
20080033369 | Kohlbrenner et al. | Feb 2008 | A1 |
20080033393 | Edwards et al. | Feb 2008 | A1 |
20080051711 | Mounce et al. | Feb 2008 | A1 |
20080051730 | Bikovsky | Feb 2008 | A1 |
20080059133 | Edwards et al. | Mar 2008 | A1 |
20080097381 | Moberg et al. | Apr 2008 | A1 |
20080108951 | Jerde et al. | May 2008 | A1 |
20080140006 | Eskuri et al. | Jun 2008 | A1 |
20080140018 | Enggaard et al. | Jun 2008 | A1 |
20080147004 | Mann et al. | Jun 2008 | A1 |
20080167641 | Hansen et al. | Jul 2008 | A1 |
20080188813 | Miller et al. | Aug 2008 | A1 |
20080208138 | Lim et al. | Aug 2008 | A1 |
20080215006 | Thorkild | Sep 2008 | A1 |
20080215013 | Felix-Faure | Sep 2008 | A1 |
20080215015 | Cindrich et al. | Sep 2008 | A1 |
20080243087 | Enggaard et al. | Oct 2008 | A1 |
20080249473 | Rutti et al. | Oct 2008 | A1 |
20080262436 | Olson | Oct 2008 | A1 |
20080269687 | Chong et al. | Oct 2008 | A1 |
20080269723 | Mastrototaro et al. | Oct 2008 | A1 |
20080274630 | Shelton et al. | Nov 2008 | A1 |
20080294143 | Tanaka et al. | Nov 2008 | A1 |
20080306449 | Kristensen et al. | Dec 2008 | A1 |
20080312601 | Cane | Dec 2008 | A1 |
20080319383 | Byland et al. | Dec 2008 | A1 |
20080319416 | Yodfat et al. | Dec 2008 | A1 |
20090012478 | Weston | Jan 2009 | A1 |
20090041805 | Walker | Feb 2009 | A1 |
20090048347 | Cohen et al. | Feb 2009 | A1 |
20090054750 | Jennewine | Feb 2009 | A1 |
20090069784 | Estes et al. | Mar 2009 | A1 |
20090076383 | Toews et al. | Mar 2009 | A1 |
20090076453 | Mejlhede et al. | Mar 2009 | A1 |
20090088694 | Carter et al. | Apr 2009 | A1 |
20090088731 | Campbell et al. | Apr 2009 | A1 |
20090093763 | Gonnelli et al. | Apr 2009 | A1 |
20090093792 | Gross et al. | Apr 2009 | A1 |
20090093793 | Gross et al. | Apr 2009 | A1 |
20090105650 | Wiegel et al. | Apr 2009 | A1 |
20090124977 | Jensen | May 2009 | A1 |
20090143730 | De Polo et al. | Jun 2009 | A1 |
20090143735 | De Polo et al. | Jun 2009 | A1 |
20090149830 | Spector | Jun 2009 | A1 |
20090182277 | Carter | Jul 2009 | A1 |
20090204076 | Liversidge | Aug 2009 | A1 |
20090209896 | Selevan | Aug 2009 | A1 |
20090234319 | Marksteiner | Sep 2009 | A1 |
20090240240 | Hines et al. | Sep 2009 | A1 |
20090253973 | Bashan et al. | Oct 2009 | A1 |
20090259176 | Yairi | Oct 2009 | A1 |
20090281585 | Katzman et al. | Nov 2009 | A1 |
20090299288 | Sie et al. | Dec 2009 | A1 |
20090299290 | Moberg | Dec 2009 | A1 |
20090299397 | Ruan et al. | Dec 2009 | A1 |
20090326459 | Shipway et al. | Dec 2009 | A1 |
20090326509 | Muse et al. | Dec 2009 | A1 |
20100030156 | Beebe et al. | Feb 2010 | A1 |
20100030198 | Beebe et al. | Feb 2010 | A1 |
20100049128 | McKenzie et al. | Feb 2010 | A1 |
20100049144 | McConnell et al. | Feb 2010 | A1 |
20100057057 | Hayter et al. | Mar 2010 | A1 |
20100076382 | Weston | Mar 2010 | A1 |
20100076412 | Rush et al. | Mar 2010 | A1 |
20100094255 | Nycz et al. | Apr 2010 | A1 |
20100100076 | Rush et al. | Apr 2010 | A1 |
20100100077 | Rush et al. | Apr 2010 | A1 |
20100106098 | Atterbury et al. | Apr 2010 | A1 |
20100121314 | Iobbi | May 2010 | A1 |
20100137790 | Yodfat | Jun 2010 | A1 |
20100137831 | Tsals | Jun 2010 | A1 |
20100145303 | Yodfat et al. | Jun 2010 | A1 |
20100145305 | Alon | Jun 2010 | A1 |
20100162548 | Leidig | Jul 2010 | A1 |
20100168607 | Miesel | Jul 2010 | A1 |
20100168683 | Cabiri | Jul 2010 | A1 |
20100198157 | Gyrn et al. | Aug 2010 | A1 |
20100204657 | Yodfat et al. | Aug 2010 | A1 |
20100234767 | Sarstedt | Sep 2010 | A1 |
20100234830 | Straessler et al. | Sep 2010 | A1 |
20100241065 | Moberg et al. | Sep 2010 | A1 |
20100264931 | Lindegger et al. | Oct 2010 | A1 |
20100274112 | Hoss et al. | Oct 2010 | A1 |
20100274192 | Mernoe | Oct 2010 | A1 |
20100280499 | Yodfat et al. | Nov 2010 | A1 |
20100331826 | Field et al. | Dec 2010 | A1 |
20110034900 | Yodfat et al. | Feb 2011 | A1 |
20110054399 | Chong et al. | Mar 2011 | A1 |
20110054400 | Chong et al. | Mar 2011 | A1 |
20110066131 | Cabiri | Mar 2011 | A1 |
20110092915 | Olson et al. | Apr 2011 | A1 |
20110112504 | Causey et al. | May 2011 | A1 |
20110125056 | Merchant | May 2011 | A1 |
20110160654 | Hanson et al. | Jun 2011 | A1 |
20110160666 | Hanson et al. | Jun 2011 | A1 |
20110160669 | Gyrn et al. | Jun 2011 | A1 |
20110172645 | Moga et al. | Jul 2011 | A1 |
20110172745 | Na et al. | Jul 2011 | A1 |
20110178463 | Cabiri | Jul 2011 | A1 |
20110178472 | Cabiri | Jul 2011 | A1 |
20110201998 | Pongpairochana et al. | Aug 2011 | A1 |
20110224616 | Slate et al. | Sep 2011 | A1 |
20110238031 | Adair et al. | Sep 2011 | A1 |
20110245773 | Estes et al. | Oct 2011 | A1 |
20110270160 | Mernoe | Nov 2011 | A1 |
20110282282 | Lorenzen et al. | Nov 2011 | A1 |
20110282296 | Harms et al. | Nov 2011 | A1 |
20110295205 | Kaufmann et al. | Dec 2011 | A1 |
20110313238 | Reichenbach et al. | Dec 2011 | A1 |
20110319861 | Wilk | Dec 2011 | A1 |
20110319919 | Curry et al. | Dec 2011 | A1 |
20120004602 | Hanson et al. | Jan 2012 | A1 |
20120010594 | Holt et al. | Jan 2012 | A1 |
20120022344 | Kube | Jan 2012 | A1 |
20120022496 | Causey et al. | Jan 2012 | A1 |
20120022499 | Anderson et al. | Jan 2012 | A1 |
20120029431 | Hwang et al. | Feb 2012 | A1 |
20120035546 | Cabiri | Feb 2012 | A1 |
20120041364 | Smith | Feb 2012 | A1 |
20120041387 | Bruggemann et al. | Feb 2012 | A1 |
20120041414 | Estes et al. | Feb 2012 | A1 |
20120071828 | Tojo et al. | Mar 2012 | A1 |
20120096953 | Bente, IV et al. | Apr 2012 | A1 |
20120096954 | Vazquez et al. | Apr 2012 | A1 |
20120101436 | Bazargan et al. | Apr 2012 | A1 |
20120108933 | Liang et al. | May 2012 | A1 |
20120129362 | Hampo et al. | May 2012 | A1 |
20120160033 | Kow et al. | Jun 2012 | A1 |
20120165733 | Bazargan et al. | Jun 2012 | A1 |
20120165780 | Bazargan et al. | Jun 2012 | A1 |
20120172817 | Bruggemann et al. | Jul 2012 | A1 |
20120226234 | Bazargan et al. | Sep 2012 | A1 |
20120259282 | Alderete, Jr. et al. | Oct 2012 | A1 |
20130012875 | Gross et al. | Jan 2013 | A1 |
20130068319 | Plumptre et al. | Mar 2013 | A1 |
20130085457 | Schiff et al. | Apr 2013 | A1 |
20130089992 | Yang | Apr 2013 | A1 |
20130096509 | Avery et al. | Apr 2013 | A1 |
20130110049 | Cronenberg et al. | May 2013 | A1 |
20130133438 | Kow et al. | May 2013 | A1 |
20130190693 | Ekman et al. | Jul 2013 | A1 |
20130237953 | Kow et al. | Sep 2013 | A1 |
20130245595 | Kow et al. | Sep 2013 | A1 |
20130245596 | Cabiri et al. | Sep 2013 | A1 |
20130253419 | Favreau | Sep 2013 | A1 |
20130253420 | Favreau | Sep 2013 | A1 |
20130253421 | Favreau | Sep 2013 | A1 |
20130267895 | Hemmingsen | Oct 2013 | A1 |
20130296799 | Degtiar et al. | Nov 2013 | A1 |
20130304021 | Cabiri | Nov 2013 | A1 |
20130310753 | Cabiri | Nov 2013 | A1 |
20130323699 | Edwards et al. | Dec 2013 | A1 |
20130331791 | Gross et al. | Dec 2013 | A1 |
20130338584 | Mounce et al. | Dec 2013 | A1 |
20140018735 | Causey et al. | Jan 2014 | A1 |
20140055073 | Favreau | Feb 2014 | A1 |
20140055076 | Favreau | Feb 2014 | A1 |
20140058349 | Bazargan et al. | Feb 2014 | A1 |
20140083517 | Moia et al. | Mar 2014 | A1 |
20140094755 | Bazargan et al. | Apr 2014 | A1 |
20140121633 | Causey et al. | May 2014 | A1 |
20140128807 | Moberg et al. | May 2014 | A1 |
20140128835 | Moberg et al. | May 2014 | A1 |
20140135692 | Alderete, Jr. et al. | May 2014 | A1 |
20140135694 | Moberg et al. | May 2014 | A1 |
20140142499 | Moberg et al. | May 2014 | A1 |
20140148784 | Anderson et al. | May 2014 | A1 |
20140148785 | Moberg et al. | May 2014 | A1 |
20140163522 | Alderete, Jr. et al. | Jun 2014 | A1 |
20140174223 | Gross et al. | Jun 2014 | A1 |
20140194819 | Maule et al. | Jul 2014 | A1 |
20140194854 | Tsals | Jul 2014 | A1 |
20140207064 | Yavorsky | Jul 2014 | A1 |
20140207065 | Yavorsky | Jul 2014 | A1 |
20140207066 | Yavorsky | Jul 2014 | A1 |
20140213975 | Clemente et al. | Jul 2014 | A1 |
20140236087 | Alderete, Jr. et al. | Aug 2014 | A1 |
20140261758 | Wlodarczyk et al. | Sep 2014 | A1 |
20150119798 | Gross et al. | Apr 2015 | A1 |
20150374926 | Gross et al. | Dec 2015 | A1 |
20160030665 | Cabiri | Feb 2016 | A1 |
20160296716 | Cabiri et al. | Oct 2016 | A1 |
20160346478 | Bar-El et al. | Dec 2016 | A1 |
Number | Date | Country |
---|---|---|
1505535 | Jun 2004 | CN |
1747683 | Mar 2006 | CN |
1863566 | Nov 2006 | CN |
101090749 | Dec 2007 | CN |
101227943 | Jul 2008 | CN |
101448536 | Jun 2009 | CN |
101522235 | Sep 2009 | CN |
101541362 | Sep 2009 | CN |
201692438 | Jan 2011 | CN |
201941304 | Aug 2011 | CN |
102186733 | Sep 2011 | CN |
102378638 | Mar 2012 | CN |
1064693 | Sep 1959 | DE |
19717107 | Nov 1998 | DE |
0017412 | Oct 1980 | EP |
0222656 | May 1987 | EP |
0401179 | Dec 1990 | EP |
1003581 | Nov 2000 | EP |
1219312 | Jul 2002 | EP |
1530979 | May 2005 | EP |
1666080 | Jun 2006 | EP |
2060606 | May 2009 | EP |
2498589 | Sep 2012 | EP |
2770136 | Apr 1999 | FR |
H07-194701 | Aug 1995 | JP |
H09-505758 | Jun 1997 | JP |
2001-512992 | Aug 2001 | JP |
2002-505601 | Feb 2002 | JP |
2002-507459 | Mar 2002 | JP |
2002-528676 | Sep 2002 | JP |
2003-501157 | Jan 2003 | JP |
2003-527138 | Sep 2003 | JP |
2003-534061 | Nov 2003 | JP |
2004-501721 | Jan 2004 | JP |
2004-512100 | Apr 2004 | JP |
2005-523127 | Aug 2005 | JP |
2005-270629 | Oct 2005 | JP |
2007-509661 | Apr 2007 | JP |
2008-534131 | Aug 2008 | JP |
2008-220961 | Sep 2008 | JP |
2009-502273 | Jan 2009 | JP |
9009202 | Aug 1990 | WO |
9307922 | Apr 1993 | WO |
9407553 | Apr 1994 | WO |
9513838 | May 1995 | WO |
9609083 | Mar 1996 | WO |
9632975 | Oct 1996 | WO |
9700091 | Jan 1997 | WO |
9710012 | Mar 1997 | WO |
9733638 | Sep 1997 | WO |
9857683 | Dec 1998 | WO |
9929151 | Jun 1999 | WO |
9959665 | Nov 1999 | WO |
0025844 | May 2000 | WO |
200130421 | May 2001 | WO |
200172357 | Oct 2001 | WO |
0187384 | Nov 2001 | WO |
0189607 | Nov 2001 | WO |
0189613 | Nov 2001 | WO |
0202165 | Jan 2002 | WO |
0234315 | May 2002 | WO |
200238204 | May 2002 | WO |
0272182 | Sep 2002 | WO |
03090833 | Nov 2003 | WO |
04000397 | Dec 2003 | WO |
2004032990 | Apr 2004 | WO |
2004105841 | Dec 2004 | WO |
2005018703 | Mar 2005 | WO |
2005037350 | Apr 2005 | WO |
2005072795 | Aug 2005 | WO |
2006037434 | Apr 2006 | WO |
06069380 | Jun 2006 | WO |
2006102676 | Sep 2006 | WO |
2006104806 | Oct 2006 | WO |
2006121921 | Nov 2006 | WO |
2007017052 | Feb 2007 | WO |
2007051563 | May 2007 | WO |
2007056504 | May 2007 | WO |
2008001377 | Jan 2008 | WO |
2008014908 | Feb 2008 | WO |
2008057976 | May 2008 | WO |
2008072229 | Jun 2008 | WO |
2008076459 | Jun 2008 | WO |
2008078318 | Jul 2008 | WO |
2009044401 | Apr 2009 | WO |
2009046989 | Apr 2009 | WO |
2009125398 | Oct 2009 | WO |
2009144085 | Dec 2009 | WO |
2010078227 | Jul 2010 | WO |
2010078242 | Jul 2010 | WO |
2010089313 | Aug 2010 | WO |
2011075105 | Jun 2011 | WO |
2011090955 | Jul 2011 | WO |
2011090956 | Jul 2011 | WO |
2011156373 | Dec 2011 | WO |
2012032411 | Mar 2012 | WO |
2012040528 | Mar 2012 | WO |
2012160157 | Nov 2012 | WO |
2014179774 | Nov 2014 | WO |
2015114158 | Aug 2015 | WO |
Entry |
---|
Office Action dated Sep. 9, 2015 in U.S. Appl. No. 13/643,470 by Alon. |
U.S. Appl. No. 14/850,450 by Gross, filed Sep. 10, 2015. |
U.S. Appl. No. 14/861,478 by Cabiri, filed Sep. 22, 2015. |
U.S. Appl. No. 14/880,673 by Cabiri, filed Oct. 12, 2015. |
Office Action dated Sep. 30, 2015 in U.S. Appl. No. 13/667,739 by Cabiri. |
Office Action dated Sep. 18, 2015 in U.S. Appl. No. 13/874,085 by Cabiri. |
Partial European Search Report dated Nov. 24, 2015 in EP Application No. 14166592.7. |
Office Action dated Dec. 1, 2015 in CN Application No. 201410289204.1. |
Office Action dated Nov. 4, 2013 in EP Application No. 11 709 234.6. |
Office Action dated Dec. 17, 2013 in JP Application No. 2012-529808. |
Office Action dated Dec. 10, 2013 in CN Application No. 201180006567.4. |
Office Action dated Jan. 8, 2014 in U.S. Appl. No. 13/521,167 by Cabiri. |
U.S. Appl. No. 29/479,307 by Norton, filed Jan. 14, 2014. |
U.S. Appl. No. 14/193,692 by Gross, filed Feb. 28, 2014. |
Office Action dated Feb. 4, 2014 in EP Application No. 11 707 942.6. |
English translation of an Office Action dated Mar. 5, 2014 in CN Application No. 200880117084.X. |
Int'l Search Report and Written Opinion dated Apr. 3, 2014 in Int'l Application No. PCT/US2013/078040. |
Extended European Search Report dated Mar. 27, 2014 in EP Application No. 14154717.4. |
Office Action dated Feb. 28, 2014 in CN Application No. 201180006571.0. |
U.S. Appl. No. 14/258,661 by Cabiri, filed Apr. 22, 2014. |
Int'l Search Report and Written Opinion dated Jan. 7, 2014 in Int'l Application No. PCT/US2013/065211. |
Office Action dated May 23, 2014 in U.S. Appl. No. 13/472,112 by Cabiri. |
Office Action dated Jun. 3, 2014 in JP Application No. 2010-527595. |
Office Action dated Jul. 7, 2014 in U.S. Appl. No. 12/244,666 by Gross. |
Int'l Search Report and Written Opinion dated Jul. 31, 2014 in Int'l Application No. PCT/US2014/033598. |
Extended European Search Report dated Aug. 7, 2014 in EP Application No. 1417477.4. |
Office Action dated Aug. 6, 2014 in EP Application No. 11 707 942.6. |
Office Action dated Sep. 2, 2014 in JP Application No. 2012-550069. |
Office Action dated Sep. 2, 2014 in JP Application No. 2012-550068. |
Office Action dated Aug. 26, 2014 in CN Application No. 201180006567.4. |
Int'l Preliminary Report on Patentability dated Oct. 9, 2014 in Int'l Application No. PCT/US2013/033118. |
Office Action dated Oct. 9, 2014 in U.S. Appl. No. 13/873,335. |
Office Action dated Nov. 5, 2014 in U.S. Appl. No. 13/643,470 by Alon. |
U.S. Appl. No. 14/553,399 by Cabiri, filed Nov. 25, 2014. |
Office Action dated Nov. 2, 2014 in CN Application No. 201180006571.0. |
Office Action dated Nov. 21, 2014 in U.S. Appl. No. 13/472,112 by Cabiri. |
Office Action dated Nov. 21, 2014 in U.S. Appl. No. 13/429,840 by Cabiri. |
Int'l Preliminary Report on Patentability dated Nov. 27, 2014 in Int'l Application No. PCT/US2013/039465. |
U.S. Appl. No. 14/593,051 by Gross, filed Jan. 9, 2015. |
U.S. Appl. No. 14/683,193 by Cabiri, filed Apr. 10, 2015. |
Office Action dated Feb. 20, 2015 in U.S. Appl. No. 13/521,181 by Cabiri. |
Office Action dated Feb. 24, 2015 in U.S. Appl. No. 14/258,661 by Cabiri. |
U.S. Appl. No. 14/638,525 by Filman, filed Mar. 4, 2015. |
Extended European Search Report dated Feb. 23, 2015 in EP Application No. 14166596.8. |
Office Action dated Mar. 10, 2015 in U.S. Appl. No. 13/643,470 by Alon. |
Office Action dated Mar. 10, 2015 in U.S. Appl. No. 12/244,666 by Gross. |
Extended European Search Report dated Feb. 23, 2015 in EP Application No. 14166591.9. |
Office Action dated Mar. 10, 2015 in CN Application No. 201180006567.4. |
Office Action dated Mar. 31, 2015 in JP Application No. 2012-550068. |
Webpage description of Daikyo Crystal Zenith® polymer, Manufactured by Daikyo Seiko, Ltd. (Jan. 6, 2009). |
Webpage description of Copaxone® , Manufactured by Teva Pharmaceutical Industries Ltd. . (Jan. 6, 2009). |
Int'l Preliminary Report on Patentability dated May 14, 2015 in Int'l Application No. PCT/US2013/065211. |
Office Action dated May 7, 2015 in JP Application No. 2012-550069. |
Office Action dated May 13, 2015 in CN Application No. 201380025566.3. |
U.S. Appl. No. 14/715,791 by Cabiri, filed May 19, 2015. |
Office Action dated May 1, 2015 in U.S. Appl. No. 14/638,525 by Filman. |
Office Action dated Jun. 4, 2015 in U.S. Appl. No. 13/667,739 by Cabiri. |
Int'l Search Report and Written Opinion dated Jul. 6, 2017 in Int'l Application No. PCT/US2017/022966. |
Daikyo Crystal Zenith® polymer, Manufactured by Daikyo Seiko, Ltd. (Jun. 25, 2008). |
Copaxone® , Manufactured by Teva Pharmaceutical Industries Ltd. (2009). |
Int'l Search Report dated May 13, 2009 in Int'l Application No. PCT/IL2008/001312. |
Int'l Preliminary Report on Patentability dated Apr. 7, 2010 in Int'l Application No. PCT/IL2008/001312; Written Opinion. |
Int'l Search Report dated Apr. 26, 2010 in Int'l Application No. PCT/US2009/069552. |
Office Action dated Apr. 5, 2010 in U.S. Appl. No. 12/244,666. |
Office Action dated Sep. 21, 2010 in U.S. Appl. No. 12/244,666. |
Office Action dated Apr. 5, 2010 in U.S. Appl. No. 12/244,688. |
Office Action dated Sep. 2, 2010 in U.S. Appl. No. 12/244,688. |
Office Action dated Sep. 30, 2010 in U.S. Appl. No. 12/689,250. |
Int'l Search Report dated Jan. 12, 2011 in Int'l Application No. PCT/US2010/048556; Written Opinion. |
U.S. Appl. No. 60/997,459, filed Oct. 2, 2007. |
U.S. Appl. No. 12/559,563, filed Sep. 15, 2009. |
U.S. Appl. No. 12/689,249, filed Jan. 19, 2010. |
U.S. Appl. No. 12/689,250, filed Jan. 19, 2010. |
International Preliminary Report on Patentability dated on Jul. 5, 2011 in International Application No. PCT/US2009/069552; Written Opinion. |
Office Action dated Jul. 13, 2011 in U.S. Appl. No. 12/559,563. |
Int'l Preliminary Report on Patentability dated Sep. 1, 2011 in Int'l Application No. PCT/US2010/048556. |
Office Action dated Sep. 6, 2011 in U.S. Appl. No. 12/345,818. |
Office Action dated Feb. 21, 2012 in U.S. Appl. No. 12/689,249. |
Int'l Search Report dated Jun. 17, 2011 in Int'l Application No. PCT/US2011/021604. |
Int'l Search Report dated Oct. 12, 2011 in Int'l Application No. PCT/US2011/021605. |
Office Action dated Oct. 28, 2011 in U.S. Appl. No. 12/615,828. |
Int'l Search Report dated Sep. 22, 2011 in Int'l Application No. PCT/IL11/00368; Written Opinion. |
U.S. Appl. No. 13/521,181 by Cabiri, filed Jul. 9, 2012. |
U.S. Appl. No. 13/521,167 by Cabiri, filed Jul. 9, 2012. |
Office Action dated May 16, 2012 in U.S. Appl. No. 12/615,828. |
Office Action dated Jul. 2, 2012 in U.S. Appl. No. 13/272,555. |
Office Action dated May 3, 2012 in CN Application No. 200880117084.X. |
U.S. Appl. No. 13/472,112 by Cabiri, filed May 15, 2012. |
U.S. Appl. No. 13/429,840 by Cabiri, filed Mar. 26, 2012. |
Int'l Preliminary Report on Patentability dated Aug. 2, 2012 in Int'l Application No. PCT/US2011/021604. |
U.S. Appl. No. 13/643,470 by Alon, filed Oct. 25, 2012. |
U.S. Appl. No. 13/733,516 by Cabiri, filed Jan. 3, 2013. |
Office Action dated Jan. 8, 2013 in JP Application No. 2010-527595. |
Int'l Preliminary Report on Patentability dated Feb. 7, 2013 in Int'l Application No. PCT/US2011/021604. |
Int'l Preliminary Report on Patentability dated Feb. 7, 2013 in Int'l Application No. PCT/US2011/021605. |
English translation of an Office Action dated Jan. 30, 2013 in CN Application No. 200880117084.X. |
U.S. Appl. No. 13/873,335 by Filman, filed Apr. 30, 2013. |
U.S. Appl. No. 13/892,905 by Cabiri, filed May 13, 2013. |
U.S. Appl. No. 13/874,121 by Degtiar, filed Apr. 30, 2013. |
U.S. Appl. No. 13/874,085 by Cabiri, filed Apr. 30, 2013. |
U.S. Appl. No. 13/874,017 by Cabiri, filed Apr. 30, 2013. |
Int'l Search Report and Written Opinion dated Jul. 26, 2013 in Int'l Application No. PCT/US2012/039465. |
Int'l Search Report and Written Opinion dated Aug. 5, 2013 in Int'l Application No. PCT/US2013/033118. |
U.S. Appl. No. 13/964,651 by Gross, filed Aug. 12, 2013. |
Office Action dated Aug. 15, 2013 in CN Application No. 200880117084.X. |
Office Action dated Oct. 9, 2013 in IL Application No. 208634. |
Office Action dated Nov. 5, 2013 in JP Application No. 2010-527595. |
Office Action dated Sep. 29, 2013 in CN Application No. 201080040968.7. |
Office Action dated Jul. 31, 2015 in U.S. Appl. No. 13/521,181 by Cabiri. |
Office Action dated Aug. 13, 2015 in U.S. Appl. No. 14/553,399 by Cabiri. |
Int'l Preliminary Report on Patentability dated Jul. 16, 2015 in Int'l Application No. PCT/US2013/078040. |
Notice of Allowance dated Aug. 24, 2015 in U.S. Appl. No. 29/479,307 by Norton. |
West Introduces the Daikyo Crystal Zenith RU Prefillable Syringe, Pharmaceutical Online, Jun. 2008, downloaded from webpage: http://www.pharmaceuticalonline.com/article.mvc/west-introduces-prefillable-syringe-system, Download date: Jan. 2009, original posting date: Jun. 2008, 2 pages. |
Office Action dated May 25, 2016 in U.S. Appl. No. 14/874,017 by Cabiri. |
Extended European Search Report dated Feb. 13, 2017 in EP Application No. 16171626.1. |
Extended European Search Report dated Mar. 8, 2016 in EP Application No. 14166592.7. |
Extended European Search Report dated Jul. 31, 2017 in EP Application No. 16190054.3. |
Number | Date | Country | |
---|---|---|---|
20160346478 A1 | Dec 2016 | US |